Department of Neurosurgery, University Hospital Bonn, 53127 Bonn, Germany.
Division of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn, 53127 Bonn, Germany.
Curr Oncol. 2024 Apr 24;31(5):2410-2419. doi: 10.3390/curroncol31050180.
Therapeutic management of patients with leptomeningeal carcinomatosis (LC) may require treatment of concomitant hydrocephalus (HC) in addition to intrathecal chemotherapy (ITC). Ventriculoperitoneal shunts (VPS) equipped with a valve for manual deactivation of shunt function and a concomitant reservoir for application of ITC pose an elegant solution to both problems. The present study evaluates indication, feasibility, and safety of such a modified shunt/reservoir design (mS/R). All patients with LC aged ≥ 18 years who had undergone mS/R implantation between 2013 and 2020 at the authors' institution were further analyzed. ITC was indicated following the recommendation of the neuro-oncological tumor board and performed according to a standardized protocol. Sixteen patients with LC underwent mS/R implantation for subsequent ITC and concomitant treatment of HC. Regarding HC-related clinical symptoms, 69% of patients preoperatively exhibited lethargy, 38% cognitive impairment, and 38% (additional) visual disturbances. Postoperatively, 86% of patients achieved subjective improvement of HC-related symptoms. Overall, postoperative complications occurred in three patients (19%). No patient encountered cancer treatment-related complications. The present study describes a combination procedure consisting of a standard VPS-system and a standard reservoir for patients suffering from LC and HC. No cancer treatment-related complications occurred, indicating straightforward handling and thus safety.
治疗性管理患有软脑膜癌病 (LC) 的患者可能需要除鞘内化疗 (ITC) 外还治疗并发的脑积水 (HC)。配备有用于手动停用分流器功能的阀门和同时用于应用 ITC 的储液器的脑室腹膜分流器 (VPS) 为这两个问题提供了一个优雅的解决方案。本研究评估了这种改良分流器/储液器设计 (mS/R) 的适应证、可行性和安全性。作者机构在 2013 年至 2020 年间对所有接受 mS/R 植入术的年龄≥18 岁的 LC 患者进行了进一步分析。根据神经肿瘤学肿瘤委员会的建议,对 ITC 进行了指示,并根据标准化方案进行了操作。16 例 LC 患者接受 mS/R 植入以进行随后的 ITC 和并发 HC 治疗。关于与 HC 相关的临床症状,69%的患者术前表现出昏睡,38%认知障碍,38%(额外)视力障碍。术后,86%的患者 HC 相关症状得到主观改善。总体而言,三名患者(19%)发生术后并发症。没有患者发生与癌症治疗相关的并发症。本研究描述了一种组合程序,包括标准的 VPS 系统和用于患有 LC 和 HC 的患者的标准储液器。没有发生与癌症治疗相关的并发症,表明处理简单,因此安全。